Page 18 - Flipbook

CheckMate -214: Intermediate-/Poor-Risk Patients

Median OS, mo (95% CI) Median PFS, mo (95% CI)

Minimum Nivolumab + Nivolumab +

Follow-Up, mo Ipilimumab Sunitinib Ipilimumab Sunitinib

(n = 425) (n = 422) (n = 425) (n = 422)

NR (28.2-NE) 26.0 (22.1-NE) 11.6 (8.7-15.5) 8.4 (7.0-10.8)

17.5 1 HR (99.8% CI) HR (99.1% CI)

0.63 (0.44-0.89); P <.001 0.82 (0.64-1.05); P = .03

NR (35.6-NE) 26.6 (22.1-33.4) 8.2 (6.9-10.0) 8.3 (7.0-8.8)

30 2 HR (95% CI) HR (95% CI)

0.66 (0.54-0.80); P <.0001 0.77 (0.65-0.90); P = .0014

47.0 (35.6-NE) 26.6 (22.1-33.5) 11.6 (8.4-15.5) 8.3 (7.0-10.8)
42 3 HR (95% CI) HR (95% CI)

0.66 (0.55-0.80); P <.0001 0.75 (0.62-0.90); P = .0015

48.1 (35.6-NE) 26.6 (22.1-33.5) 11.2 (8.4-16.1) 8.3 (7.0-10.8)
48 4 HR (95% CI) HR (95% CI)

0.65 (0.54-0.78); P <.0001 0.74 (0.62-0.88); P = .0015

47.0 (35.4-57.4) 26.6 (22.1-33.5) 11.6 (8.4-16.5) 8.3 (7.0-10.4)
60 5 HR (95% CI) HR (95% CI)

0.68 (0.58-0.81); P <.0001 0.73 (0.61-0.87); P = .0004

1. Motzer RJ et al. N Engl J Med. 2018. PMID: 29562145. 2. Motzer RJ et al. Lancet Oncol. 2019. PMID: 31427204. 3. Motzer RJ et al. J Immunother Cancer. 2020. PMID: 32661118. 4. Albiges L. et al., ESMO Open, 2021. PMID: 33246931. 5. Motzer R.J. et al.,
ESMO Annual Congress, 2021.